Sociedad Americana de Hirudoterapia

Genetically Encoded Multivalent Elastin-Like Polypeptide-Haemadin Fusion Proteins for Prolonged Antithrombotic Protection

Research article published in Biomacromolecules (2026)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportDesarrollo de fármacosEnsayos clínicosSeguridad y control de infeccionesFarmacología salivalYang H et al. · Biomacromolecules, 2026

Abstract

The clinical application of peptide therapeutics is often constrained by their short plasma half-life, necessitating frequent administration and resulting in undesirable pharmacokinetic fluctuations and side effects. Here, we developed a genetically encodable multivalent fusion protein platform that combines haemadin, a selective thrombin inhibitor derived from terrestrial leeches, with an elastin-like polypeptide (ELP) partner via factor Xa (FXa)-cleavable peptide linkers. This platform enables tunable drug loading, long-term release, and stimuli-responsive activation of antithrombotic activity. After subcutaneous injection, the fusion protein undergoes temperature-triggered ELP condensation to form an in situ depot that slowly releases an inactivated prodrug, which remains inert in circulation until thrombus-associated FXa cleave the linker to liberate active haemadin on demand. We achieved high-yield expression and facile nonchromatographic purification of the fusion protein. Subcutaneous administration resulted in significant prolongation of antithrombotic protection postinjection. This approach holds strong potential to enhance the safety, efficacy, and dosing convenience of peptide therapy.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsElastinAnimalsRecombinant Fusion ProteinsPeptidesFibrinolytic AgentsHumansThrombosisMiceElastin-Like PolypeptidesFactor Xa

Resumen

The clinical application of peptide therapeutics is often constrained by their short plasma half-life, necessitating frequent administration and resulting in undesirable pharmacokinetic fluctuations and side effects.

Por qué esto importa para la hirudoterapia

This study developed a genetically encodable multivalent fusion protein platform combining haemadin—a selective thrombin inhibitor derived from terrestrial leeches—with an elastin-like polypeptide partner to provide prolonged, stimuli-responsive antithrombotic protection. After subcutaneous injection, the fusion protein forms a depot that slowly releases an inactivated prodrug, which is liberated by thrombus-associated factor Xa to produce active haemadin on demand. This research is directly relevant to the American Society of Hirudotherapy and leech secretome research, as it leverages a leech-derived bioactive compound for innovative antithrombotic drug delivery. However, the abstract does not specify the study's experimental model or clinical stage, and the work involves engineered fusion proteins rather than live hirudotherapy or crude leech extracts.

Citación

Genetically Encoded Multivalent Elastin-Like Polypeptide-Haemadin Fusion Proteins for Prolonged Antithrombotic Protection

Yang H et al. · Biomacromolecules, 2026

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.